Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 17/20 | 1.00 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.64 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.64 |
| ▸ | HTT | P42858 | 1/20 | 0.62 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20379744 | 1.00 | NAMPT (1.00) | NAMPTROCK2ROCK1HTTMAPK3 | |
| SCHEMBL29882094 | 0.83 | NAMPT (1.00) | NAMPTROCK2 | |
| SCHEMBL20379987 | 0.83 | NAMPT (1.00) | NAMPTROCK2 | |
| SCHEMBL10269652 | 0.82 | NAMPT (0.70) | NAMPTROCK2ROCK1MAPK3MAPK1 | |
| SCHEMBL20380035 | 0.81 | NAMPT (1.00) | NAMPT | |
| SCHEMBL29881696 | 0.81 | NAMPT (1.00) | NAMPT | |
| SCHEMBL4525925 | 0.79 | ROCK2 (1.00) | NAMPTROCK2ROCK1HTTMAPK1 | |
| SCHEMBL7701855 | 0.78 | NAMPT (0.64) | NAMPTROCK2ROCK1HTT | |
| SCHEMBL11616834 | 0.78 | HTT (1.00) | NAMPTROCK2ROCK1HTT | |
| SCHEMBL29882324 | 0.76 | NAMPT (1.00) | NAMPTROCK2ROCK1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230116770-A1 | SMALL MOLECULE ACTIVATORS OF NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE (NAMPT) AND USES THEREOF | Sanford Burnham Prebys Medical Discovery Institute | 2023-04-13 | — | — | US | disclosed |
| US-11452717-B2 | Small molecule activators of nicotinamide phosphoribosyltransferase (NAMPT) and uses thereof | Sanford Burnham Prebys Medical Discovery Institute (US) | 2022-09-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11452717-B2 | Small molecule activators of nicotinamide phosphoribosyltransferase (NAMPT) and uses thereof | NAMPT, NAPRT, NNT | NAMPT 1/4885ROCK2 2967/4885ROCK1 3446/4885 |
| US-20230116770-A1 | SMALL MOLECULE ACTIVATORS OF NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE (NAMPT) AND USES THEREOF | NAMPT, NAPRT, NNT | NAMPT 1/4885ROCK2 2967/4885ROCK1 3446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.